CN112807238A - 一种皮肤抗炎舒缓修护凝胶及其制备方法 - Google Patents
一种皮肤抗炎舒缓修护凝胶及其制备方法 Download PDFInfo
- Publication number
- CN112807238A CN112807238A CN202110264500.6A CN202110264500A CN112807238A CN 112807238 A CN112807238 A CN 112807238A CN 202110264500 A CN202110264500 A CN 202110264500A CN 112807238 A CN112807238 A CN 112807238A
- Authority
- CN
- China
- Prior art keywords
- skin
- inflammatory
- gel
- soothing
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 45
- 230000008439 repair process Effects 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title abstract description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 18
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims abstract description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 9
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 9
- 229960000458 allantoin Drugs 0.000 claims abstract description 9
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims abstract description 9
- 229960000401 tranexamic acid Drugs 0.000 claims abstract description 9
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 8
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 7
- 239000001140 aloe barbadensis leaf extract Substances 0.000 claims abstract description 7
- -1 purslane extract Substances 0.000 claims abstract description 7
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 7
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 7
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 5
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 5
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 5
- 239000003906 humectant Substances 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims description 21
- 235000011399 aloe vera Nutrition 0.000 claims description 20
- 230000001804 emulsifying effect Effects 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000010438 heat treatment Methods 0.000 claims description 6
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 5
- 229920006037 cross link polymer Polymers 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- 235000002961 Aloe barbadensis Nutrition 0.000 claims description 3
- RWAXQWRDVUOOGG-UHFFFAOYSA-N N,2,3-Trimethyl-2-(1-methylethyl)butanamide Chemical compound CNC(=O)C(C)(C(C)C)C(C)C RWAXQWRDVUOOGG-UHFFFAOYSA-N 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 claims description 3
- 229960001631 carbomer Drugs 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229940089508 methyl diisopropyl propionamide Drugs 0.000 claims description 3
- CFJYNSNXFXLKNS-UHFFFAOYSA-N p-menthane Chemical compound CC(C)C1CCC(C)CC1 CFJYNSNXFXLKNS-UHFFFAOYSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 229940061720 alpha hydroxy acid Drugs 0.000 claims description 2
- 150000001280 alpha hydroxy acids Chemical class 0.000 claims description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 244000186892 Aloe vera Species 0.000 claims 1
- UJNOLBSYLSYIBM-WISYIIOYSA-N [(1r,2s,5r)-5-methyl-2-propan-2-ylcyclohexyl] (2r)-2-hydroxypropanoate Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1OC(=O)[C@@H](C)O UJNOLBSYLSYIBM-WISYIIOYSA-N 0.000 claims 1
- 239000003974 emollient agent Substances 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 238000007689 inspection Methods 0.000 claims 1
- 229920005862 polyol Polymers 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 75
- 230000000694 effects Effects 0.000 abstract description 40
- 206010061218 Inflammation Diseases 0.000 abstract description 35
- 230000004054 inflammatory process Effects 0.000 abstract description 30
- 208000024891 symptom Diseases 0.000 abstract description 14
- 230000001737 promoting effect Effects 0.000 abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 206010000496 acne Diseases 0.000 abstract description 6
- 229940067866 dandelion extract Drugs 0.000 abstract description 5
- 235000020691 dandelion extract Nutrition 0.000 abstract description 5
- 239000001845 taraxacum officinale leaf extract Substances 0.000 abstract description 5
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 4
- 208000020154 Acnes Diseases 0.000 abstract description 4
- 229940064064 purslane extract Drugs 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 241000251468 Actinopterygii Species 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 235000013372 meat Nutrition 0.000 abstract description 2
- 238000011084 recovery Methods 0.000 abstract description 2
- 210000004927 skin cell Anatomy 0.000 abstract description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 abstract 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 abstract 1
- 229940100524 ethylhexylglycerin Drugs 0.000 abstract 1
- 206010015150 Erythema Diseases 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 18
- 241001116389 Aloe Species 0.000 description 17
- 208000003251 Pruritus Diseases 0.000 description 13
- 231100000321 erythema Toxicity 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 12
- 230000002757 inflammatory effect Effects 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 10
- 230000000638 stimulation Effects 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 206010042674 Swelling Diseases 0.000 description 8
- 210000000245 forearm Anatomy 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000036407 pain Effects 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 230000003467 diminishing effect Effects 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000007794 irritation Effects 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- 235000001855 Portulaca oleracea Nutrition 0.000 description 3
- 241000219304 Portulacaceae Species 0.000 description 3
- 241000207929 Scutellaria Species 0.000 description 3
- 206010040844 Skin exfoliation Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000002085 irritant Substances 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000005808 skin problem Effects 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- YDQWDHRMZQUTBA-UHFFFAOYSA-N Aloe emodin Chemical compound C1=CC=C2C(=O)C3=CC(CO)=CC(O)=C3C(=O)C2=C1O YDQWDHRMZQUTBA-UHFFFAOYSA-N 0.000 description 2
- AFHJQYHRLPMKHU-XXWVOBANSA-N Aloin Natural products O=C1c2c(O)cc(CO)cc2[C@H]([C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O2)c2c1c(O)ccc2 AFHJQYHRLPMKHU-XXWVOBANSA-N 0.000 description 2
- 206010003399 Arthropod bite Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010016807 Fluid retention Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 208000012641 Pigmentation disease Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 241000245665 Taraxacum Species 0.000 description 2
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 2
- 206010053615 Thermal burn Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- AFHJQYHRLPMKHU-OSYMLPPYSA-N aloin A Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@H]1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-OSYMLPPYSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- AFHJQYHRLPMKHU-UHFFFAOYSA-N isobarbaloin Natural products OC1C(O)C(O)C(CO)OC1C1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 AFHJQYHRLPMKHU-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011158 quantitative evaluation Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 239000002344 surface layer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- HKIKAXXIWJHWLY-ZIIYPAMZSA-N Aloesin Chemical compound C=12OC(CC(=O)C)=CC(=O)C2=C(C)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HKIKAXXIWJHWLY-ZIIYPAMZSA-N 0.000 description 1
- HKIKAXXIWJHWLY-QEVGBQTESA-N Aloesin Natural products O=C(CC=1Oc2c([C@H]3[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O3)c(O)cc(C)c2C(=O)C=1)C HKIKAXXIWJHWLY-QEVGBQTESA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040830 Skin discomfort Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- CPUHNROBVJNNPW-UHFFFAOYSA-N aloin A Natural products OC1C(O)C(O)C(CO)OC1OC1C2=CC(CO)=CC(O)=C2C(=O)C2=C(O)C=CC=C21 CPUHNROBVJNNPW-UHFFFAOYSA-N 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 235000020980 bad eating habits Nutrition 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- KERBAAIBDHEFDD-UHFFFAOYSA-N n-ethylformamide Chemical compound CCNC=O KERBAAIBDHEFDD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/62—Coated
- A61K2800/622—Coated by organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种皮肤抗炎舒缓修护凝胶及其制备方法,该凝胶包括亚微米包裹凉润剂、蒲公英提取物、传明酸、黄芩提取物、马齿苋提取物、库拉索芦荟叶汁粉、透明质酸钠、尿囊素、甘草酸二钾、生物糖胶‑2、凝胶剂、pH调节剂、1,3‑丙二醇、1,2‑己二醇、苯氧乙醇、乙基己基甘油、苯扎氯铵和库拉索芦荟叶汁。本发明具有抗炎、舒缓皮脍敏感症状、修护皮肤、防止敏感发生、平衡皮肤水油、增加皮肤柔润程度,激活肌肤细胞活力,促进受损肌肤恢复,同时还具有祛痘、抑痘功效。
Description
技术领域
本发明涉及一种皮肤抗炎舒缓修护凝胶及其制备方法,属于化妆品技术领域。
背景技术
随着生活环境变化、睡眠不足、电器电子产品辐射影响、过度使用药物等因素,造成皮肤表层屏障作用减弱,越来越多的人出现皮肤长期处于敏感或易敏状态,造在各种各样的皮肤问题,出现皮肤发红、出红疹、瘙痒、结团、脓疮、皮肤溃疡等,严重因扰正常生活,影响个人形象与生活质量,甚致继发感染导致严重的继发病症。
随着社会竞争加剧、工作压力大、生活节奏加快、饮食习惯不良,越来越多的人出现皮肤皮脂分泌紊乱,水油不平衡,皮肤随环境变化时而缺水干燥,时而油腻,毛孔无法及时调节,排泄不畅导致皮脂淤积,引发皮肤炎症反应,从而导致痤疮、粉刺、暗疮、痘痘等,如不及时处理,就会导致红肿痛痒等现象,炎症消除后会形成局部色素沉积、痘坑,严重影响美观。这些皮肤问题都和皮脂腺分泌异常及皮肤保水能力不足、内分泌紊乱、生活饮食习惯、环境因素、使用不当的化妆品等因素相关。
近年来,随着化妆品行业的不断发展,以及人们对“回归自然”消费理念的日益提升,特别是天然草本植物成分倍受欢迎。
目前市场上出现的抗炎、舒缓、修护产品非常多,但配方技术落后于现代科技发展水平,功效成份较为单一,适应面受到局限,效果不全面,无法适应复杂条作下或多种因素同时作用导致的皮肤敏感与炎症反应问题,功效上无法达到消费者对功能性护肤品的要求。
发明内容
本发明的目的是针对现有抗炎舒缓产品的不足,提供一种具有舒缓修复、抗菌消炎、促进损伤愈合作用,对割伤、擦伤、伤口溃烂、烫伤、皮肤瘙痒、蚊虫叮咬、青春痘等有明显的镇定舒缓、抗炎修护作用的皮肤抗炎舒缓修护凝胶。
本发明的另一目的是提供一种上述修护凝胶的制备方法。
本发明为实现上述目的,采用以下技术方案:
一种皮肤抗炎舒缓修护凝胶,其特征在于包括以下质量百分比组分:
本发明一种皮肤抗炎舒缓修护凝胶,包括以下质量百分比组分:
本发明一种皮肤抗炎舒缓修护凝胶,包括以下质量百分比组分:
亚微米包裹凉润剂为包含薄荷烷甲酰乙胺、薄荷醇乳酸酯、甲基二异丙基丙酰胺、纤维素、多元醇和油酯的缓释微粒。由薄荷烷甲酰乙胺、薄荷醇乳酸酯、甲基二异丙基丙酰胺与纤维素、多元醇、油酯经过亚微米包裹工艺后形成缓释微粒,减低薄荷醇类物质作用过快对皮肤产生不适感,并且还可以明显延长凉润舒爽感的时间,可产生明显的即时镇定效果,减轻皮肤瘙痒、红肿疼痛等急性症状。
库拉索芦荟叶汁粉,芦荟中的葸醌类化合物主要有芦荟素、芦荟泻素、芦荟苦素、芦荟乌鲁辛、芦荟酊、芦荟甙、芦荟大黄甙、芦荟大黄素等,这些天然成分具有杀菌、抑菌、消炎、解毒、促进伤口愈合、增强机体免疫力,促进创伤愈合等作用。用于本发明的皮肤抗炎舒缓修护凝胶中,具有舒缓修复、抗菌消炎、促进损伤愈合作用。
黄芩提取物主要成分为黄芩苷,通过抑制多种炎性细胞的表达,抑制环氧合酶COX-2的活性,减少炎症因子PGE2的生成,能有效制过敏性炎症渗出,降低毛细血管通透性,有抗组织胺与抗乙酰胆碱作用。用于本发明的皮肤抗炎舒缓修护凝胶中,具有舒缓、抗炎、减轻红肿、疼痛、瘙痒等炎症反应。
马齿苋提取物能够减少炎症因子白介素的分泌,从而舒缓皮肤炎症,对疼痛和红肿有明显的的抑制能力,同时对长期使用激素类化妆品产生的皮肤过敏有明显的改善作用,改善皮肤干燥、粗糙、发红、脱皮等过敏症状,对痘痘、粉刺等化脓性皮肤问题有很好的治疗效果。用于本发明的皮肤抗炎舒缓修护凝胶中,具有舒缓消炎,抗红肿,抑制皮肤瘙痒等功效作用。
蒲公英提取物富含蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种活性成分,具有极强的抗菌消炎作用,在炎症初起时能避免多形棱白细胞和吞噬细胞参与反应,避免炎症反应加重。蒲公英提取物能刺激皮肤SOD活性增高,并直接参与清除超氧自由基,阻断其对皮肤的损伤作用,减轻超氧自由基对皮肤组织的刺激和炎症损伤,使炎症症状明显减轻,并加快皮损部位和病灶的修复。用于本发明的皮肤抗炎舒缓修护凝胶中,具有抗炎,消除红肿,促进损伤愈合作用。
芦荟、马齿苋、黄芩及蒲公英提取物天然成分,四种萃取物协同作用,具有显著的舒缓修复、抗菌消炎、促进损伤愈合作用,对割伤、擦伤、伤口溃烂、烫伤、皮肤瘙痒、蚊虫叮咬、青春痘等有很强的抗炎修护作用,同时还具有激活细胞活力,能促进胶原蛋白的合成以及清除皮肤氧自由基。
甘草酸二钾,具有抑菌抗炎,抗过敏作用,协助美白,止痒,可有效预防皮肤受刺激时敏感发炎现象。对日照引起的炎症具有消炎镇静作用。用于本发明中,具有促渗性能,加快功效成分吸收,抗炎舒敏作用。
尿囊素能软化角质层蛋白,促进细胞的生长和新陈代谢,加速伤口的愈合,有效的治疗皮肤损伤。在本发明中具有保湿、抗炎、促地损伤愈合作用。
传明酸,一种蛋白酶抑制剂,能抑制蛋白酶的水解催化作用,从而抑制黑色素细胞的活性,从而彻底阻绝因紫外线照射而形成黑色素的途径,防止皮肤色素沉积。在本发明中,促进活性成分的吸收,同时可以抑制炎症反应引起的色素沉积。
甘草酸二钾、尿囊素、传明酸三者按一定比例进行复配后,对减轻皮肤红、肿敏感症状,表现出非常显著的效果,从而避免皮肤破损,大大降低后期感染发生机率。
透明质酸钠、生物糖胶-2、1,3-丙二醇进行组合复配,在皮肤表面及浅层形成立体化的水分控制层,调节皮肤水分含量,预防皮肤受急性症状刺激后的过度反应与过度调节,抑制皮肤表层过度角质化,避免皮肤粗糙,增强毛孔口柔韧性,保障皮脂排泄通畅,避免皮肤因缺水多油,皮脂淤积引起的皮肤炎症。同时透明质酸钠、生物糖胶-2在皮肤表面的超微膜还可吸收皮脂,减轻皮肤油腻感。该水分控制层在皮肤表面形成极薄且具有韧性的保护膜,具有保湿、隔离、稳定功效成分、保护皮肤创面的多重作用。
本发明中的凝胶剂选自卡波姆、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物和葡聚糖硫酸酯钠中的一种或两种。
本发明中的pH调节剂为三乙醇胺、氢氧化钠、氨甲基丙醇、阿尔法羟基酸、水杨酸中的一种。
一种皮肤抗炎舒缓修护凝胶的制备方法,包括以下步骤:
a、在真空乳化锅中投入库拉索芦荟叶汁和凝胶剂,搅拌升温;
b、将透明质酸钠和1,3-丙二醇分散均匀后加入真空乳化锅,继续升温至60~85℃,保温搅拌15-25min,开始降温;
c、降温至60~65℃,将尿囊素、甘草酸二钾投入真空乳化锅中,搅拌均匀;
d、继续降温至45℃以下时,将传明酸、亚微米包裹凉润剂、蒲公英提取物、库拉索芦荟叶汁粉、生物糖胶-2、马齿苋提取物、黄芩提取物投入真空乳化锅中,搅拌均匀;
e、抽真空至负0.06MPa,1200rpm均质5分钟,搅拌均匀;
f、将1,2-己二醇、苯氧乙醇、乙基己基甘油、苯扎氯铵投入真空乳化锅中,搅拌均匀;
g、加入pH调节剂调节pH值,搅拌均匀排除真空后出料即可。
出料后陈化检测合格后再灌装。优选陈化1-2天。
本发明相对于现有技术而言,有益效果如下:
芦荟、马齿苋、黄芩及蒲公英天然成分的提取物,协同作用,可以舒缓修复皮肤,抗菌消炎并促进损伤愈合,同时还具有激活细胞活力,对促进胶原蛋白的合成以及清除自由基作用;亚微米包裹技术的应用使清凉剂效果柔和而又持久,克服了清凉剂短暂而强烈的作用效果,满足了适用于敏感肌肤护理的需求,亚微米包裹清凉剂、甘草酸二钾、尿囊素、传明酸按一定比例进行组合与复配后,减轻皮肤瘙痒、红肿疼痛等急性症状,控制因皮肤炎症反应而导致的局部皮肤色素沉积和结缔组织增生,预防色斑色块与疤痕形成,与四种植物萃取成分表现出很强的协同作用效果,大大减轻了皮肤急性症状带来的痛苦。
本发明具有抗炎、舒缓皮脍敏感症状、修护皮肤、防止敏感发生、平衡皮肤水油、增加皮肤柔润程度,激活肌肤细胞活力,促进受损肌肤恢复,同时还具有祛痘、抑痘功效。
附图说明
图1为实施例1-3和对比例的抗刺激实验的临床评价结果;
图2为实施例1-3和对比例的抗刺激实验皮肤红斑变化结果;
图3为实施例1-3和对比例的刺激舒缓实验临床评价结果;
图4为为实施例1-3和对比例的刺激舒缓实验皮肤红班值变化结果。
具体实施方式
下面结合具体实施例对本发明作进一步详细介绍:
实施例1-3的各组分质量百分比如表1所示。
表1:
组分名称 | 实施例1(%) | 实施例2(%) | 实施例3(%) |
亚微米包裹凉润剂 | 0.50 | 0.50 | 0.50 |
蒲公英提取物 | 2.50 | 2.20 | 4.00 |
传明酸 | 0.20 | 0.15 | 0.15 |
黄芩提取物 | 0.25 | 0.35 | 0.30 |
马齿苋提取物 | 3.20 | 4.50 | 3.00 |
库拉索芦荟叶汁粉 | 0.50 | —— | —— |
透明质酸钠 | 0.10 | 0.12 | 0.12 |
尿囊素 | 0.20 | 0.15 | 0.18 |
甘草酸二钾 | 0.15 | 0.18 | 0.18 |
生物糖胶-2 | 0.80 | 0.70 | 0.70 |
凝胶剂 | 0.90 | 1.00 | 1.00 |
pH调节剂 | 0.90 | 0.60 | 0.50 |
1,3-丙二醇 | 5.00 | 6.00 | 6.00 |
1,2-己二醇 | 0.55 | 0.60 | 0.60 |
苯氧乙醇 | 0.50 | 0.40 | 0.40 |
乙基己基甘油 | 0.10 | 0.15 | 0.15 |
苯扎氯铵 | 0.06 | 0.08 | 0.08 |
库拉索芦荟叶汁 | 余量 | 余量 | 余量 |
其中,实施例1中的凝胶剂为卡波姆,pH调节剂为三乙醇胺,实施例2中的凝胶剂为丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物,pH调节剂为氨甲基丙醇,实施例3中的凝胶剂为丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物,pH调节剂为氢氧化钠。
实施例1-3的制备方法包括以下步骤:
a、在真空乳化锅中投入库拉索芦荟叶汁和凝胶剂,开启搅拌并升温;
b、将透明质酸钠和1,3-丙二醇分散均匀后加入真空乳化锅,继续升温至60~85℃,保温搅拌15-25min,开始降温;
c、降温至60~65℃,将尿囊素、甘草酸二钾投入真空乳化锅中,搅拌均匀;
d、继续降温至45℃以下时,将传明酸、亚微米包裹凉润剂、蒲公英提取物、库拉索芦荟叶汁粉、生物糖胶-2、马齿苋提取物、黄芩提取物投入真空乳化锅中,搅拌均匀;
e、抽真空至负0.06MPa,1200rpm均质5分钟,搅拌10min搅拌均匀;
f、将1,2-己二醇、苯氧乙醇、乙基己基甘油、苯扎氯铵投入真空乳化锅中,搅拌10min至均匀;
g、加入pH调节剂调节pH值,搅拌10min,排除真空后出料即可。
实施例1-3的产品,贮存1-2天后质量评定合格即可灌装。
对实施例1~3所得的皮肤抗炎舒缓修护凝胶进行功效临床评价测试,均效果明显,其中实施例3表现出了优秀的性能,深受试用者的欢迎,通过高透明的丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物、1,3-丙二醇和高保湿的透明质酸钠、生物糖胶-2在皮肤表面及浅层形成立体化的水分控制层,并在皮肤表面可以形成良好透气性和柔韧性的保水性高分子隔离膜,保护受损或炎症敏感肌肤。通过以芦荟、马齿苋、黄芩、蒲公英四种植物提取物优化组合为舒缓修复、抗菌消炎、损伤愈合作用主体,从而达到抗菌消炎、舒缓修复、促进损伤皮肤愈合的效果。加上由亚微米包裹凉润剂、甘草酸二钾、尿囊素、传明酸组合成的协同作用组合,快速缓解红肿痛痒等急性症状,实现抗敏舒缓、消炎止痒的即时效果,并防止因皮肤炎症反应而导致的局部皮肤色素沉积和结缔组织增生,预防色斑色块与疤痕形成。
实施例1~3效果评价实验。
抗炎抗刺激和炎症刺激舒缓功效:采用随机单盲安慰剂对照人体实验,通过志愿者临床评价和无创性定量评价分析,测试产品抵抗因十二烷基硫酸钠(SDS)引起的刺激和舒缓SDS引起刺激两个方面的功效。为防止抗炎抗刺激实验和炎症刺激舒缓实验对志愿者左右前臂产生交叉影响,本实验采用左前臂做抗炎抗刺激实验对象,右前臂做炎症刺激舒缓实验对象。
抗炎抗刺激实验:实验前,将40名志愿者左前臂用清水清洗干净,静坐30分钟。将左前臂分成4块区域,依次均匀涂抹适量样品(1~3号样品分别对应实施例1~3;4号样品为某品牌芦荟胶),手臂实验区域依次循环涂抹样品、对照品。15分钟后,在4块区域分别覆盖含10%十二烷基硫酸钠(SDS)溶液的贴片(面积:2cm×2cm),每隔15分钟分别滴加0.2mLSDS溶液(约4滴),45分钟后撤去贴片,用棉球蘸清水轻缓擦拭实验区域。
炎症刺激舒缓实验:实验前,将40名志愿者右前臂用清水清洗干净,静坐30分钟,将右前臂分成4块区域,在4块区域覆盖含10%十二烷基硫酸钠(SDS)溶液的贴片(面积:2cm×2cm),每隔15分钟分别滴加0.2mLSDS溶液(约4滴),45分钟后撤去贴片。用棉球蘸清水轻缓擦拭实验区域,5分钟依次均匀涂抹适量样品(1~3号样品分别对应实施例1~3;4号样品为某品牌芦荟胶),手臂实验区域依次循环涂抹对照品、样品;从测试次日起统一由实验室人员于测试前半小时涂抹样品一次。
评价方法:
临床评价:自觉症状:瘙痒、灼热、刺痛、紧绷感;体征:红斑、干燥/脱屑。自觉症状和体征均采用半定量评分。
抗炎抗刺激和炎症刺激舒缓实验临床评价半定量评分标准如表2所示。
表2:
1、抗炎抗刺激实验分别在含SDS贴片撤去后0min,5min,15min,30min,60min,120min,240min进行半定量评分。
2、炎症刺激舒缓实验分别在涂抹皮肤抗炎舒缓修护凝胶样品后0min,5min,15min,30min,60min,120min,240min进行半定量评分。
无创性定量评价,无创性定量评价主要测定以下两种指标:
1、皮肤红斑值测定:采用Mexameter MX18仪测定(德国C&K公司)。
2、抗炎抗刺激实验分别在含SDS贴片撤去后0h,0.5h,1h,2h,4h,1d,3d,7d进行上述指标的测试。
3、炎症刺激舒缓实验分别在涂抹皮肤抗炎舒缓修护凝胶样品后0h,0.5h,1h,2h,4h,1d,3d,7d进行上述指标的测试。
4、炎症刺激舒缓实验分别在涂抹皮肤抗炎舒缓修护凝胶样品后0h,0.5h,1h,2h,4h,1d,3d,7d进行上述指标的测试。
效果评价实验结果。
抗炎抗刺激实验:临床半定量评价一种最直接的人体感官实验,可以直观地表征产品对刺激引起的瘙痒、灼热、刺痛、紧绷感或红斑、干燥、脱屑等症状的治疗效果。其分值越低,表示产品效果越好。
实施例1-3与对比例的实验结果如图1所示。
1、从临床评价分值分析,实施例1~3样品均能在15~20分钟分值能降到理想水平,表明皮肤抗炎舒缓修护凝胶在人体自觉症状和敏感体征消除方面,明显优于4号某品牌芦荟胶样品,且15~20分钟时效果最佳。
2、从分值降低速度方面分析,实施例1~3样品降低的速度明显较4号某品牌芦荟胶样品要快,表明在减缓不适感觉快慢方面,皮肤抗炎舒缓修护凝胶能快速消除炎症刺激引起的皮肤不适感觉。
(注:在刺激性试验中,人体在SDS贴片去除后,会有约5分钟的严重不适感,图中前5分钟数值上升属正常生理反应。)
抗刺激实验皮肤红斑值的变化:皮肤受到刺激后会产生不同程度的红斑现象。皮肤红斑值的变化表征在测试周期内,各皮肤抗炎舒缓凝胶样品对刺激引起红斑消退的影响。皮肤红斑值越低、下降越快表示效果越好。实施例1-3与对比例的实验结果如图2所示。
通过比较可以看出,实施例1~3样品的红斑值同比均低于4号某品牌芦荟胶样品红斑值,表明皮肤抗炎舒缓凝胶样品具很好的抵抗SDS引起的炎症红斑的效果,效果明显优于4号某品牌芦荟胶样品。
在红斑值降低速度方面,实施例1~3样品明显优于4号某品牌芦荟胶样品,表明皮肤抗炎舒缓凝胶样品在消除红斑快慢方面,有明显优势。
炎症刺激舒缓实验结果如图3所示,从临床评价分值分析,实施例1~3样品分值同比均低于4号某品牌芦荟胶样品,表明在人体自觉症状和敏感体征消除方面,皮肤抗炎舒缓凝胶具有非常明显的效果。
从分值降低速度快慢分析,实施例1~3样品分值约在5分钟时降到最低值,表明皮肤抗炎舒缓凝胶样品具有瞬时消除不适感觉的效果,且效果明显,与4号某品牌芦荟胶样品相比具有明显优势。
刺激舒缓实验皮肤红斑值变化结果如图4所示。
从红斑数值分析,实施例1~3样品的红斑值同比均低于4号某品牌芦荟胶样品,效果明显,表明皮肤抗炎舒缓凝胶在舒缓因SDS引起的炎性红斑方面效果明显。
从红斑值降低速度分析,实施例1~3样品降低速度上明显快于4号某品牌芦荟胶样品,表明皮肤抗炎舒缓凝胶在消除红斑快慢效果方面,具有明显优势。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (8)
4.根据权利要求1所述的一种皮肤抗炎舒缓修护凝胶,其特征在于所述的亚微米包裹凉润剂为包含薄荷烷甲酰乙胺、薄荷醇乳酸酯、甲基二异丙基丙酰胺、纤维素、多元醇和油酯的缓释微粒。
5.根据权利要求1所述的一种皮肤抗炎舒缓修护凝胶,其特征在于所述的凝胶剂选自卡波姆、丙烯酸(酯)类/C10-30烷醇丙烯酸酯交联聚合物和葡聚糖硫酸酯钠中的一种或两种。
6.根据权利要求1所述的一种皮肤抗炎舒缓修护凝胶,其特征在于所述的pH调节剂为三乙醇胺、氢氧化钠、氨甲基丙醇、阿尔法羟基酸、水杨酸中的一种。
7.一种权利要求1-6中任一项所述皮肤抗炎舒缓修护凝胶的制备方法,其特征在于包括以下步骤:
a、在真空乳化锅中投入库拉索芦荟叶汁和凝胶剂,搅拌升温;
b、将透明质酸钠和1,3-丙二醇分散均匀后加入真空乳化锅,继续升温至60~85℃,保温搅拌15-25min,开始降温;
c、降温至60~65℃,将尿囊素、甘草酸二钾投入真空乳化锅中,搅拌均匀;
d、继续降温至45℃以下时,将传明酸、亚微米包裹凉润剂、蒲公英提取物、库拉索芦荟叶汁粉、生物糖胶-2、马齿苋提取物、黄芩提取物投入真空乳化锅中,搅拌均匀;
e、抽真空至负0.06MPa,1200rpm均质5分钟,搅拌均匀;
f、将1,2-己二醇、苯氧乙醇、乙基己基甘油、苯扎氯铵投入真空乳化锅中,搅拌均匀;
g、加入pH调节剂调节pH值,搅拌均匀排除真空后出料即可。
8.根据权利要求7所述皮肤抗炎舒缓修护凝胶的制备方法,其特征在于出料后陈化1-2天检测合格后灌装。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110264500.6A CN112807238A (zh) | 2021-03-11 | 2021-03-11 | 一种皮肤抗炎舒缓修护凝胶及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110264500.6A CN112807238A (zh) | 2021-03-11 | 2021-03-11 | 一种皮肤抗炎舒缓修护凝胶及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112807238A true CN112807238A (zh) | 2021-05-18 |
Family
ID=75863100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110264500.6A Pending CN112807238A (zh) | 2021-03-11 | 2021-03-11 | 一种皮肤抗炎舒缓修护凝胶及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112807238A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115944576A (zh) * | 2022-11-21 | 2023-04-11 | 烟台新时代健康产业日化有限公司 | 一种用于敏感肌肤修复的组合物、面膜液及面膜 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101543467A (zh) * | 2009-04-01 | 2009-09-30 | 完美(中国)日用品有限公司 | 一种芦荟凝胶及其制备方法 |
CN104274342A (zh) * | 2013-07-03 | 2015-01-14 | 吴文兵 | 一种通过植物萃取的防治疲劳驾驶的精华露 |
WO2018113446A1 (zh) * | 2016-12-22 | 2018-06-28 | 张文健 | 一种玫瑰精华营养护肤芦荟胶 |
CN109431924A (zh) * | 2018-10-12 | 2019-03-08 | 广东博禧高新科技有限公司 | 一种芦荟修护抗炎精华液及制备方法 |
CN109512760A (zh) * | 2018-12-07 | 2019-03-26 | 广州天玺生物科技有限公司 | 一种复方植物舒敏修护精华的制备方法 |
-
2021
- 2021-03-11 CN CN202110264500.6A patent/CN112807238A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101543467A (zh) * | 2009-04-01 | 2009-09-30 | 完美(中国)日用品有限公司 | 一种芦荟凝胶及其制备方法 |
CN104274342A (zh) * | 2013-07-03 | 2015-01-14 | 吴文兵 | 一种通过植物萃取的防治疲劳驾驶的精华露 |
WO2018113446A1 (zh) * | 2016-12-22 | 2018-06-28 | 张文健 | 一种玫瑰精华营养护肤芦荟胶 |
CN109431924A (zh) * | 2018-10-12 | 2019-03-08 | 广东博禧高新科技有限公司 | 一种芦荟修护抗炎精华液及制备方法 |
CN109512760A (zh) * | 2018-12-07 | 2019-03-26 | 广州天玺生物科技有限公司 | 一种复方植物舒敏修护精华的制备方法 |
Non-Patent Citations (2)
Title |
---|
新日化贸易拓展(香港)有限公司: "HydroSal® SalCool", 《WWW.NEWJAF.COM/STARPRODUCTS/INFO.ASPX?ITEMID=1077》 * |
王建新: "《化妆品植物原料大全》", 31 August 2016, 中国纺织出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115944576A (zh) * | 2022-11-21 | 2023-04-11 | 烟台新时代健康产业日化有限公司 | 一种用于敏感肌肤修复的组合物、面膜液及面膜 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105687055B (zh) | 一种眼部修护精华液及其制备方法 | |
CN1663559B (zh) | 皮肤健全剂 | |
CN108969429B (zh) | 一种祛痘精华液 | |
CN109157451B (zh) | 一种祛痘洁面乳 | |
CN106265264B (zh) | 一种祛痘组合物及其制备方法 | |
CN105769698A (zh) | 一种不含防腐剂的化妆品组合物及其应用 | |
CN110575412A (zh) | 一种添加药用孔菌层提取物的毛孔专用美容液及其制备方法 | |
CN109260075B (zh) | 一种祛痘调理水 | |
WO2024045952A1 (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
CN112426386A (zh) | 一种控油祛痘功效组合物及凝胶 | |
CN111588815B (zh) | 一种外用祛痘中药组合物及其应用与含有该组合物的祛痘平衡精华 | |
CN112168766A (zh) | 一种抗炎舒缓芦荟胶及其制备方法 | |
CN111671692A (zh) | 一种祛痘组合物及其制备方法与应用 | |
CN112516066B (zh) | 一种控油组合物及其在化妆品中的应用 | |
CN108295022B (zh) | 一种祛痘组合物及其制备方法 | |
CN109330947A (zh) | 一种控油祛痘爽肤水及其制备方法 | |
CN112807238A (zh) | 一种皮肤抗炎舒缓修护凝胶及其制备方法 | |
CN112402308A (zh) | 一种多效舒缓保湿水及其制备方法 | |
CN115919686A (zh) | 增强肌肤屏障的安肤水及其制备方法 | |
CN115054566B (zh) | 一种抗头皮衰老组合物及其制备方法 | |
CN108078868B (zh) | 一种用于护肤品的抗过敏组合物 | |
CN112370404B (zh) | 一种保湿美白组合物、其制备方法及应用 | |
CN109568227A (zh) | 一种祛黑眼圈凝露及其制备方法 | |
CN112057388A (zh) | 一种用于妊娠纹修复的乳霜及其制备方法 | |
CN107648084B (zh) | 一种用于宠物皮肤保健的植物精油及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210518 |